Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study

Yogesh N.V. Reddy, Gregory D. Lewis, Sanjiv J. Shah, Masaru Obokata, Omar F. Abou-Ezzedine, Marat Fudim, Jie Lena Sun, Hrishikesh Chakraborty, Steven McNulty, Martin M. LeWinter, Douglas L. Mann, Lynne W. Stevenson, Margaret M. Redfield, Barry A. Borlaug

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Objective: To characterize the obese heart failure with preserved ejection fraction (HFpEF) phenotype in a multicenter cohort. Patients and Methods: This was a secondary analysis of the randomized clinical trial RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) performed between October 1, 2008, and February 1, 2012. Patients with HFpEF were classified by body mass index (BMI) as obese (BMI≥35 kg/m2) and nonobese (BMI<30 kg/m2) for comparison. Results: Obese patients with HFpEF (n=81) were younger (median age, 64 [interquartile range (IQR), 67-79] years vs 73 [IQR, 56-70] years; P<.001) but had greater peripheral edema (31% [25] vs 9% [6]; P<.001), more orthopnea (76% [56] vs 53% [35]; P=.005), worse New York Heart Association class (P=.006), and more impaired quality of life (P<.001) as compared with nonobese patients with HFpEF (n=70). Despite more severe signs and symptoms, obese patients with HFpEF had lower N-terminal pro B-type natriuretic peptide level (median, 481 [IQR, 176-1183] pg/mL vs 825 [IQR, 380-1679] pg/mL [to convert to pmol/L, multiply by 0.118]; P=.007) and lower left atrial volume index (median, 38 [IQR, 31-47] mL/m2 vs 54 [IQR, 41-63] mL/m2; P<.001). Serum C-reactive protein (median, 5.0 [IQR, 2.4-9.9] mg/dL vs 2.7 [IQR, 1.6-5.4] mg/dL [to convert to mg/L, multiply by 10−3]; P<.001) and uric acid (median, 7.8 [IQR, 6.1-8.7] mg/dL vs 6.8 [IQR, 5.5-8.3] mg/dL; P=.03) levels were higher in obese HFpEF, indicating greater systemic inflammation, than in nonobese HFpEF. Peak oxygen consumption was impaired in obese HFpEF (median, 11.1 [IQR, 9.6-14.4] mL/kg per minute vs 13.1 [IQR, 11.3-14.7] mL/kg per minute; P=.008), as was submaximal exercise capacity (6-minute walk distance, 272 [IQR, 200-332] m vs 355 [IQR, 290-415] m; P<.0001). Conclusion: Obese HFpEF is associated with decreased quality of life, worse symptoms of heart failure, greater systemic inflammation, worse exercise capacity, and higher metabolic cost of exertion as compared with nonobese HFpEF. Further study is required to understand the pathophysiology and potential distinct treatments for patients with the obese phenotype of HFpEF. Trial Registration: clinicaltrials.gov Identifier: NCT00763867

Original languageEnglish
Pages (from-to)1199-1209
Number of pages11
JournalMayo Clinic Proceedings
Volume94
Issue number7
DOIs
StatePublished - Jul 2019

Fingerprint Dive into the research topics of 'Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study'. Together they form a unique fingerprint.

  • Cite this

    Reddy, Y. N. V., Lewis, G. D., Shah, S. J., Obokata, M., Abou-Ezzedine, O. F., Fudim, M., Sun, J. L., Chakraborty, H., McNulty, S., LeWinter, M. M., Mann, D. L., Stevenson, L. W., Redfield, M. M., & Borlaug, B. A. (2019). Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clinic Proceedings, 94(7), 1199-1209. https://doi.org/10.1016/j.mayocp.2018.11.037